Peter Wilkinson - Laboratory Senior Vice President, Chief Accounting Officer
| LH Stock | USD 246.49 1.62 0.66% |
President
Mr. Peter Wilkinson is appointed as Senior Vice President, Chief Accounting Officer of the company effective April 1, 2019. Mr. Wilkinson currently serves in the role of LabCorporations Senior Vice President, Accounting since January 2019. Prior to that, Mr. Wilkinson served as Executive Vice President and Chief Financial Officer of Syneos Health, Inc.s clinical division, a biopharmaceuticals services organization, from August 2017 to July 2018 and as Senior Vice President and Chief Accounting Officer of INC Research Holdings, Inc., a publicly traded predecessor to Syneos Health, from February 2016 to August 2017. Mr. Wilkinson also previously served as Senior Vice President in the INC Research Finance Department from April 2014 to February 2016. Prior to his position with INC Research, Mr. Wilkinson worked as a selfemployed Financial Consultant following an earlier career as a Financial and Accounting Officer at Pharmaceutical Product Development, LLC, a clinical research organization. since 2019.
| Age | 54 |
| Tenure | 6 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Peter Wilkinson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Wilkinson against Laboratory stock is an integral part of due diligence when investing in Laboratory. Peter Wilkinson insider activity provides valuable insight into whether Laboratory is net buyers or sellers over its current business cycle. Note, Laboratory insiders must abide by specific rules, including filing SEC forms every time they buy or sell Laboratory'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Wilkinson over six months ago Disposition of 894 shares by Peter Wilkinson of Laboratory at 216.57 subject to Rule 16b-3 | ||
Peter Wilkinson over a year ago Payment of tradable shares by Peter Wilkinson of Laboratory subject to Rule 16b-3 | ||
Peter Wilkinson over a year ago Exercise or conversion by Peter Wilkinson of 131 shares of Laboratory subject to Rule 16b-3 | ||
Peter Wilkinson over a year ago Sale by Peter Wilkinson of 1384 shares of Laboratory |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0405 % which means that for every $100 of assets, it generated a profit of $0.0405. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0936 %, which means that it produced $0.0936 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.06. As of now, Laboratory's Other Current Assets are increasing as compared to previous years. The Laboratory's current Total Current Assets is estimated to increase to about 4.5 B, while Intangible Assets are projected to decrease to under 2 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| William Fleming | Humana Inc | 53 | |
| George II | Humana Inc | 56 | |
| Susan Diamond | Humana Inc | 51 | |
| James Davis | Quest Diagnostics Incorporated | 62 | |
| Christopher Hunter | Humana Inc | 52 | |
| Steve Filton | Universal Health Services | 67 | |
| Marc Miller | Universal Health Services | 54 | |
| Michael Harrington | Waters | 59 | |
| Elizabeth Rae | Waters | 60 | |
| John Lynch | Waters | N/A | |
| John III | Humana Inc | N/A | |
| Carrie Manner | Quest Diagnostics Incorporated | 45 | |
| Michael Deppe | Quest Diagnostics Incorporated | 58 | |
| Marvin Pember | Universal Health Services | 66 | |
| Gabrielle Wolfson | Quest Diagnostics Incorporated | N/A | |
| Michael Prevoznik | Quest Diagnostics Incorporated | 62 | |
| Amol Chaubal | Waters | 48 | |
| James MBA | Humana Inc | 53 | |
| Sherry Buck | Waters | 55 | |
| Cynthia Zipperle | Humana Inc | 58 | |
| David Dintenfass | Humana Inc | N/A | |
Management Performance
| Return On Equity | 0.0936 | ||||
| Return On Asset | 0.0405 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Akinbolade Oyegunwa, Executive Officer | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Julia Wang, CFO VP | ||
| Jonathan DiVincenzo, Executive International | ||
| Kerrii Anderson, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Enterprise VP | ||
| John Treadwell, Vice Initiatives | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| JeanLuc Belingard, Independent Director | ||
| Sandra JD, Chief VP | ||
| Akinbolade MBA, Executive Officer | ||
| Kathryn Wengel, Independent Director | ||
| Peter Neupert, Lead Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| Richelle Parham, Independent Director | ||
| Robert Williams, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Garheng Kong, Independent Director | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0936 | ||||
| Return On Asset | 0.0405 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 26.18 B | ||||
| Shares Outstanding | 83.4 M | ||||
| Shares Owned By Insiders | 0.51 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 1.9 M | ||||
| Price To Earning | 12.69 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 8.9 | Revenue Per Share | Quarterly Revenue Growth 0.098 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.